This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing therapies in development for HDV with a focus on Eiger's lonafarnib
Ticker(s): EIGRWho's the expert?
Institution: University of Geneva
- Professor at the Departments of Specialty Medicine and of Pathology and Immunology of the University of Geneva; Chairman of the Swiss Hepatitis C Cohort Study, and member of the updating committees of the clinical practice guidelines for HCV of the EASL and the World Health Organisation.
- Research focuses on viral hepatitis, especially on the pathogenesis of metabolic alterations induced by the hepatitis C virus, i.e. steatosis and insulin resistance.
- Has participated in several clinical trials in acute and chronic HCV, authoring or co-authoring ~300 peer-reviewed manuscripts in the field of hepatology.
Interview GoalThis conversation will focus on the current treatment landscape and market size for HDV, Eiger's lonafarnib, and new therapies on the horizon.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
